Know Cancer

forgot password

Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies

Phase 1/Phase 2
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies

Breast cancer is the most common malignancy and second most common cause of cancer-specific
death among women in the United States. Despite advances in the diagnosis and treatment of
breast cancer, one third of the women who develop the disease will die of the disease,
accounting for approximately 46,300 deaths/year. While good primary therapies are available
to treat early stage breast cancer, there is a substantial failure rate to these therapies
in more advanced disease.

Advances in the understanding of the immune response to cancer have lead to the genesis of
immunotherapeutic approaches. Specifically, the development of anti-cancer vaccines holds
promise as an adjuvant and preventive therapy for patients after both primary surgical and
medical treatment for breast cancer, but who are at a high risk for recurrence. Patients
with greater than four lymph nodes positive have an 87% chance of recurrence post standard
surgical and medical therapies at 10 years. While patients with hormone receptor positive
tumors have the option to undergo hormonal therapy, recurrence is especially high among
estrogen receptor/progesterone receptor (ER/PR) negative patients. For these patients,
currently there is no good treatment option after completion of primary therapy; close
surveillance and watchful waiting is the standard.

It is this population of patients that a vaccine strategy to induce cellular immunity would
target. We propose to vaccinate these patients with an immunogenic peptide from the
HER2/neu protein. If successful, this vaccine strategy could be utilized as an adjuvant to
currently accepted first line therapy in future clinical trials.

Inclusion Criteria:

1. HER2/neu expressing tumor

2. HLA-A2+ and/or HLA-A3+ to receive the vaccine. HLA-A2- and/or HLA-A3- patients will
be eligible to be included in the control group.

3. Immunologically intact with a good performance status

4. Identified as being high or intermediate risk for recurrence

5. Without evidence of disease

6. Completion of all standard first-line therapies (but may still be on hormonal

Exclusion Criteria:

1. Tumor does not express HER2/neu

2. Not HLA-A2+ and/or HLA-A3+

3. Anergic

4. Receiving immunosuppressive therapy

5. In poor health (Karnofsky <60%, ECOG >2 and Tbili >1.5 and creatinine>2)

6. Pregnant (beta HCG+)

7. Metastatic disease or have refused standard therapies

8. Patients enrolled in other experimental protocols may enroll to this study only with
the permission of the other study PI.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

The primary endpoints are the safety and optimal dosing of the vaccine to induce an in vivo peptide-specific immune response.

Outcome Time Frame:

Time period needed to determine the maximum tolerated and optimal biologic doses.

Safety Issue:


Principal Investigator

George E Peoples, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer Vaccine Development Program


United States: Food and Drug Administration

Study ID:




Start Date:

May 2000

Completion Date:

October 2012

Related Keywords:

  • Breast Cancer
  • Breast cancer
  • Breast Neoplasms



Walter Reed National Military Medical Center Bethesda, Maryland  20889
Windber Medical Center Windber, Pennsylvania  15963